BLRX Stock Overview
A commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BioLineRx Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.27 |
| 52 Week High | ₪1.89 |
| 52 Week Low | ₪0.25 |
| Beta | 0.87 |
| 11 Month Change | -32.91% |
| 3 Month Change | -60.90% |
| 1 Year Change | -81.39% |
| 33 Year Change | -89.43% |
| 5 Year Change | -89.94% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
BioLineRx stock slips on $15M securities offering
Sep 19BioLineRx files for FDA approval of motixafortide in stem cell mobilization
Sep 12biolinerx GAAP EPS of -$0.01 beats by $0.08
Aug 16BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
Jun 29BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Jun 30biolinerx EPS beats by $0.17
May 26BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma
May 04BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer
Dec 16biolinerx EPS beats by $0.32
Nov 23BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress
Nov 18BioLineRx launches mid-stage combo study in first-line pancreatic cancer
Oct 29Shareholder Returns
| BLRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -41.3% | 4.0% | 2.2% |
| 1Y | -81.4% | 18.3% | 32.6% |
Return vs Industry: BLRX underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: BLRX underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| BLRX volatility | |
|---|---|
| BLRX Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BLRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 79 | Phil Serlin | www.biolinerx.com |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. Fundamentals Summary
| BLRX fundamental statistics | |
|---|---|
| Market cap | US$24.69m |
| Earnings (TTM) | -US$30.12m |
| Revenue (TTM) | US$17.05m |
1.4x
P/S Ratio-0.8x
P/E RatioIs BLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLRX income statement (TTM) | |
|---|---|
| Revenue | US$17.05m |
| Cost of Revenue | US$6.04m |
| Gross Profit | US$11.00m |
| Other Expenses | US$41.12m |
| Earnings | -US$30.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 64.55% |
| Net Profit Margin | -176.67% |
| Debt/Equity Ratio | 210.6% |
How did BLRX perform over the long term?
See historical performance and comparison